Cencora, Inc.

BST:ABG Stock Report

Market Cap: €46.1b

Cencora Valuation

Is ABG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABG (€234.85) is trading below our estimate of fair value (€677)

Significantly Below Fair Value: ABG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABG?

Key metric: As ABG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ABG. This is calculated by dividing ABG's market cap by their current earnings.
What is ABG's PE Ratio?
PE Ratio31.8x
EarningsUS$1.51b
Market CapUS$48.03b

Price to Earnings Ratio vs Peers

How does ABG's PE Ratio compare to its peers?

The above table shows the PE ratio for ABG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.1x
SHL Siemens Healthineers
28.6x14.2%€55.6b
ILM1 Medios
26x43.9%€334.7m
FME Fresenius Medical Care
18.8x19.3%€12.4b
CAH Cardinal Health
23x7.7%US$29.5b
ABG Cencora
31.8x14.6%€48.0b

Price-To-Earnings vs Peers: ABG is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the peer average (24.1x).

Price to Earnings Ratio vs Industry

How does ABG's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ABG 31.8xIndustry Avg. 18.7xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ABG is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the European Healthcare industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is ABG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ABG's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€234.85
€252.41
+7.5%
7.9%€275.71€217.17n/a16
Nov ’25n/a
€237.66
0%
7.6%€265.07€198.57n/a16
Oct ’25n/a
€234.01
0%
7.5%€258.39€193.56n/a16
Sep ’25n/a
€235.53
0%
7.5%€257.96€193.24n/a16
Aug ’25€223.85
€241.85
+8.0%
7.7%€265.96€199.24n/a16
Jul ’25€222.00
€237.84
+7.1%
9.0%€260.15€180.25n/a16
Jun ’25€200.20
€236.41
+18.1%
9.3%€259.25€179.62n/a15
May ’25€222.90
€238.35
+6.9%
8.6%€261.88€181.45n/a16
Apr ’25€222.60
€227.64
+2.3%
10.4%€248.00€168.09n/a16
Mar ’25€219.85
€227.64
+3.5%
10.7%€248.83€168.65n/a15
Feb ’25€212.75
€215.95
+1.5%
12.6%€245.64€168.36n/a15
Jan ’25€184.04
€193.59
+5.2%
6.7%€214.88€160.93n/a14
Dec ’24n/a
€195.09
0%
6.3%€208.24€164.35n/a13
Nov ’24n/a
€195.81
0%
8.4%€212.60€153.07n/a13
Oct ’24€177.92
€193.01
+8.5%
8.1%€210.58€151.62n/a13
Sep ’24€163.12
€189.25
+16.0%
7.9%€206.35€148.57n/a14
Aug ’24€168.26
€176.69
+5.0%
8.9%€193.21€135.16€223.8514
Jul ’24€174.02
€171.06
-1.7%
8.1%€190.13€136.20€222.0015
Jun ’24€159.86
€171.56
+7.3%
7.6%€190.73€137.29€200.2015
May ’24€150.46
€167.08
+11.0%
7.1%€188.74€137.18€222.9015
Apr ’24€147.02
€167.05
+13.6%
6.9%€185.30€137.36€222.6015
Mar ’24€145.40
€170.56
+17.3%
7.2%€188.76€139.93€219.8513
Feb ’24€148.78
€164.92
+10.8%
7.9%€182.97€135.63€212.7512
Jan ’24€150.82
€166.55
+10.4%
7.0%€183.67€139.40€184.0411
Dec ’23€162.62
€171.74
+5.6%
6.2%€188.72€150.01n/a11
Nov ’23€158.54
€175.02
+10.4%
6.4%€193.79€157.26n/a12

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%